Skip to main content
Top
Published in: Endocrine 3/2018

01-03-2018 | Editorial

Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems!

Author: Maria Fleseriu

Published in: Endocrine | Issue 3/2018

Login to get access

Excerpt

Growth hormone (GH) effects on skeletal development are well recognized. GH promotes longitudinal bone growth during childhood and attainment of adult bone mass [1, 2]. However, GH also plays a role in adult skeletal mass maintenance. Insulin-like growth factor 1 (IGF-1) influences development and function of several skeletal cell lineages. Independently of IGF-1, GH stimulates chondrocytes and osteoblasts; precursors of proliferation and differentiation. Simultaneously, bone resorption is mainly stimulated by IGF-1, whereas GH negatively modulates this effect by inducing the synthesis of osteoprotegerin by osteoblasts. Furthermore, GH may influence parathyroid hormone secretion pattern through phosphate retention, thus further influencing bone remodeling. …
Literature
1.
go back to reference A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)CrossRef A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)CrossRef
2.
go back to reference E. Varlamov, M. Fleseriu, Growth hormone deficiency and replacement effect on adult bone mass: a clinical update. Curr. Opin. Endo. Metab. Res. In Press (2018) E. Varlamov, M. Fleseriu, Growth hormone deficiency and replacement effect on adult bone mass: a clinical update. Curr. Opin. Endo. Metab. Res. In Press (2018)
3.
go back to reference G.I. Baroncelli, S. Bertelloni, C. Ceccarelli, G. Saggese, Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 83, 3150–3154 (1998)CrossRef G.I. Baroncelli, S. Bertelloni, C. Ceccarelli, G. Saggese, Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 83, 3150–3154 (1998)CrossRef
4.
go back to reference A.M. Boot, M.A.M.J. Engels, G.J.M. Boerma, E.P. Krenning, S.M.P.F. de Muinck Keizer-Schrama, Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 82, 2423–2428 (1997)PubMed A.M. Boot, M.A.M.J. Engels, G.J.M. Boerma, E.P. Krenning, S.M.P.F. de Muinck Keizer-Schrama, Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 82, 2423–2428 (1997)PubMed
5.
go back to reference S.J. Holmes, G. Economou, R.W. Whitehouse, J.E. Adams, S.M. Shalet, Reduced bone mineral density in patients with adult onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 78, 669–674 (1994)PubMed S.J. Holmes, G. Economou, R.W. Whitehouse, J.E. Adams, S.M. Shalet, Reduced bone mineral density in patients with adult onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 78, 669–674 (1994)PubMed
6.
go back to reference T. Rosen, T. Hansson, H. Granhed, J. Szucs, B.A. Bengtsson, Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. 129, 201–206 (1993)CrossRef T. Rosen, T. Hansson, H. Granhed, J. Szucs, B.A. Bengtsson, Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. 129, 201–206 (1993)CrossRef
7.
go back to reference N.A. Tritos, A. Klibanski, in Chapter Nine–Effects of Growth Hormone on Bone, ed. by F.F Casanueva. Progress in Molecular Biology and Translational Science, vol 138 (Academic Press publications, London, UK, 2016), pp. 193–211 N.A. Tritos, A. Klibanski, in Chapter Nine–Effects of Growth Hormone on Bone, ed. by F.F Casanueva. Progress in Molecular Biology and Translational Science, vol 138 (Academic Press publications, London, UK, 2016), pp. 193–211
8.
go back to reference N.A. Tritos, Skeletal health in adult growth hormone deficiency. Endocrine 52, 1–2 (2016)CrossRef N.A. Tritos, Skeletal health in adult growth hormone deficiency. Endocrine 52, 1–2 (2016)CrossRef
9.
go back to reference M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 852–860 (2014)CrossRef M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 852–860 (2014)CrossRef
10.
go back to reference G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103–110 (2016)CrossRef G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103–110 (2016)CrossRef
11.
go back to reference D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol. 3, 331–338 (2015)CrossRef D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol. 3, 331–338 (2015)CrossRef
12.
go back to reference C. Ohlsson, D. Mellstrom, D. Carlzon, E. Orwoll, O. Ljunggren, M.K. Karlsson, L. Vandenput, Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J. Bone Miner. Res. 26, 865–872 (2011)CrossRef C. Ohlsson, D. Mellstrom, D. Carlzon, E. Orwoll, O. Ljunggren, M.K. Karlsson, L. Vandenput, Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J. Bone Miner. Res. 26, 865–872 (2011)CrossRef
13.
go back to reference M. Barake, A. Arabi, N. Nakhoul, G. El-Hajj Fuleihan, S. El Ghandour, A. Klibanski, N.A. Tritos, Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. Endocrine. (2017) https://doi.org/10.1007/s12020-017-1440-0 CrossRef M. Barake, A. Arabi, N. Nakhoul, G. El-Hajj Fuleihan, S. El Ghandour, A. Klibanski, N.A. Tritos, Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. Endocrine. (2017) https://​doi.​org/​10.​1007/​s12020-017-1440-0 CrossRef
14.
go back to reference L. Holloway, L. Kohlmeier, K. Kent, R. Marcus, Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 82, 1111–1117 (1997)PubMed L. Holloway, L. Kohlmeier, K. Kent, R. Marcus, Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 82, 1111–1117 (1997)PubMed
15.
go back to reference K. Landin-Wilhelmsen, A. Nilsson, I. Bosaeus, B.A. Bengtsson, Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J. Bone Miner. Res. 18, 393–405 (2003)CrossRef K. Landin-Wilhelmsen, A. Nilsson, I. Bosaeus, B.A. Bengtsson, Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J. Bone Miner. Res. 18, 393–405 (2003)CrossRef
16.
go back to reference E. Krantz, P. Trimpou, K. Landin-Wilhelmsen, Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 100, 3251–3259 (2015)CrossRef E. Krantz, P. Trimpou, K. Landin-Wilhelmsen, Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 100, 3251–3259 (2015)CrossRef
Metadata
Title
Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems!
Author
Maria Fleseriu
Publication date
01-03-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1519-7

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.